Sat, Nov 29, 2014, 5:08 AM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Keryx Biopharmaceuticals Inc. Message Board

  • ironjinman ironjinman Nov 5, 2013 6:10 PM Flag


    I havent noticed anyone talking about this.

    In the call, Ron stated that with 1.5 million US patients in 3-5 CKD, a 7% market penetration at $10,000 dollars a year would generate 1 BILLION DOLLARS in revenue. Keep in mind that this does not include ESRD at all and is only US patients. This is huge. It tosses my original BuyOut premium price of 41-44 out the window.. Quick math would now put my BO price at $70ish. WOWZER!

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • rblconstruction Nov 5, 2013 6:56 PM Flag

      That's a lot of CasHHHHHHHHH

    • Iron, to me the most important thing which all those doctors commented about was oral administration of Z being a much safer alternative of delivering iron than compared to I-V's. It binds phosphate as well as any drug on the market, but keeping those people out of a dialysis center 3 times a week for 3 1/2 or 4 hours a day is going to be a game changer when considering the patients quality of life. Just think if you were a patient that goes for dialysis this much and one day you walk in to your Dr.'s office and he says I have something for you to take and it might just keep you from having to go to dialysis ever again. That's heavy duty !!!!!

      Sentiment: Strong Buy

    • Correct. I think Ron will hold out for a fair price. QCOR (61 million shares outstanding vs. KERX 82 million) is over $60 a share with only $230 million in revenue....why can't we be at least 1/2 of that..$30...common sense says we will get there, just wait it out like patient QCOR longs did and the rewards will come.

      Sentiment: Strong Buy

15.90+0.01(+0.06%)Nov 28 1:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
BP p.l.c.
NYSEFri, Nov 28, 2014 1:02 PM EST